These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20864368)

  • 1. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.
    Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL
    Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months.
    Barr C; Clarke JT; Ntwari A; Drouin R; Auray-Blais C
    Mol Genet Metab; 2009 Aug; 97(4):278-83. PubMed ID: 19464216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
    Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
    Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea.
    Kim JY; Hyun YY; Lee JE; Yoon HR; Kim GH; Yoo HW; Cho ST; Chun NW; Jeoung BC; Kim HJ; Kim KW; Kim SN; Kim YA; Lee HA; Lee JY; Lee YC; Lim HK; Oh KS; Son SH; Yu BH; Wee KS; Lee EJ; Lee YK; Noh JW; Kim SJ; Choi KB; Yu SH; Pyo HJ; Kwon YJ
    Korean J Intern Med; 2010 Dec; 25(4):415-21. PubMed ID: 21179280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
    Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
    Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique.
    Selvarajah M; Nicholls K; Hewitson TD; Becker GJ
    Nephrol Dial Transplant; 2011 Oct; 26(10):3195-202. PubMed ID: 21382994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
    Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
    Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
    Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
    J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb
    Auray-Blais C; Lavoie P; Boutin M; Abaoui M
    Curr Protoc Hum Genet; 2017 Apr; 93():17.26.1-17.26.12. PubMed ID: 28384397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
    Piraud M; Maire I; Froissart R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
    Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
    Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease.
    Auray-Blais C; Cyr D; Mills K; Giguère R; Drouin R
    J Inherit Metab Dis; 2007 Feb; 30(1):106. PubMed ID: 17171433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
    Abaoui M; Boutin M; Lavoie P; Auray-Blais C
    Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
    Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
    Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.
    Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P
    Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
    Lavoie P; Boutin M; Auray-Blais C
    Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.